Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biovail Locks Up Global Rights To Xenazine With Cambridge Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

The $230 million deal doubles Biovail's investment in Xenazine and is the latest indication that there is more to this is Huntington's chorea therapy than meets the eye.
Advertisement

Related Content

Biovail Partners with Alexza On Late-Stage CNS Drug For Schizophrenia Agitation
Biovail Partners with Alexza On Late-Stage CNS Drug For Schizophrenia Agitation
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2009
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2009
Business And Finance In Brief
Business And Finance In Brief
The Xenazine Model: Big Things Come In Small Packages
Prestwick Buyout Scores Huntington’s Drug For Biovail
Prestwick Buyout Scores Huntington’s Drug For Biovail

Topics

Advertisement
UsernamePublicRestriction

Register

PS069618

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel